All the news Showing 10 of 18 articles from: Genotype 4Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4 Liz Highleyman / 02 March 2016 Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, ... Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... New Merck combination pill Zepatier approved for hepatitis C treatment in the United States Keith Alcorn / 01 February 2016 Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor) and elbasvir (an NS5A inhibitor) ... Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation Liz Highleyman / 18 November 2015 A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor velpatasvir from Gilead Sciences produced sustained response in 99% of people with hepatitis C virus genotypes 1, 2, 4, 5 and 6, ... Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients Liz Highleyman / 17 November 2015 A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest phase 3 trial to ... Sofosbuvir/ledipasvir cures more than 90% of people with hepatitis C genotypes 4 and 5 Liz Highleyman / 20 May 2015 An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study ... Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4 Liz Highleyman / 13 November 2014 [Editor's Note: this article previously stated that the PEARL-I trial tested the AbbVie 3D Viekira Pak regimen for HCV genotype 4. In actuality, the study used the 2D regimen consisting of the paritaprevir coformulation without dasabuvir. The article has been corrected.] Sofosbuvir/ledipasvir without ribavirin and ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive